Skip to content

Detection of prognostic biomarkers in patients with oral squamous cell carcinoma with tissue microarray

Detection of prognostic biomarkers in patients with oral squamous cell carcinoma with tissue microarray - TMA OSCC

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00010431
Enrollment
1000
Registered
2016-11-25
Start date
2016-12-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Squamous Cell Carcinoma C01 C02 C03 C04 C05 C06

Interventions

Group 1: Patient with histologically proven primary oral squamous cell carcinoma at one the participating hospitals diagnosed since 2005. Prospectively, the following parameters will be evaluated: - T

Sponsors

Universitätsklinikum Hamburg-Eppendorf
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 18 years of age, histologically proven primary oral squamous cell carcinoma starting from 2005 or later, known TNM-status, sufficient diameter of tumor embedded in paraffin, informed consent

Exclusion criteria

Exclusion criteria: <18 years of age, no informed consent, not enough tumor (<5mm diameter) embedded in paraffin, no tam status

Design outcomes

Primary

MeasureTime frame
Detection of prognostic biomarkers with tissue microarray for the outcome in patients with OSCC

Secondary

MeasureTime frame
Risk Factors alcohol, nicotine and drugs, nutrition, oral health status, TNM-classification, HPV-status, sex, age, date of recurrent cancer, type and duration of surgical and adjuvant oncological therapy, functional outcome, date of death, cause of death, oral hygiene.

Countries

Germany

Contacts

Public ContactMax Heiland

Universitätsklinikum Hamburg-EppendorfMund-, Kiefer- und Gesichtschirurgie

mkg@uke.de040741052354

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026